Variants of GRM7 as risk factor and response to antipsychotic therapy in schizophrenia.

ABSTRACT: Genome-wide association study (GWAS) has determined the metabotropic glutamate receptor 7 (GRM7) gene as potential locus for schizophrenia risk variants; However, the relationship between the GRM7 variants and the risk of schizophrenia is still uncertain, and there are significant individual variations in response to the antipsychotic drugs. In order to identify susceptible gene and drug-response-related markers, 2413 subjects in our research were chosen for determining drug-response-related markers in schizophrenia. The rs1516569 variant (OR = 0.95, P < 3.47 × 10^-4) was a significant risk factor, and a single-nucleotide polymorphism of GRM7 gene- rs9883258 (OR = 0.84, P = 2.18 × 10^-3) has been determined as potential biomarkers for therapeutic responses of seven comm

SUBMITTER: Liang W 

PROVIDER: S-EPMC7054263 | biostudies-literature | 2020 Mar

REPOSITORIES: biostudies-literature